NO174302C - Fremgangsmåte for produksjon av en human-insulin-lignende vekstfaktor - Google Patents

Fremgangsmåte for produksjon av en human-insulin-lignende vekstfaktor

Info

Publication number
NO174302C
NO174302C NO841613A NO841613A NO174302C NO 174302 C NO174302 C NO 174302C NO 841613 A NO841613 A NO 841613A NO 841613 A NO841613 A NO 841613A NO 174302 C NO174302 C NO 174302C
Authority
NO
Norway
Prior art keywords
igf
host
human
gene
growth factor
Prior art date
Application number
NO841613A
Other languages
English (en)
Norwegian (no)
Other versions
NO841613L (no
NO174302B (no
Inventor
Philip J Barr
James P Merryweather
Guy Mullenbach
Mickey S Urdea
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of NO841613L publication Critical patent/NO841613L/no
Publication of NO174302B publication Critical patent/NO174302B/no
Publication of NO174302C publication Critical patent/NO174302C/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/65Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
NO841613A 1983-04-25 1984-04-24 Fremgangsmåte for produksjon av en human-insulin-lignende vekstfaktor NO174302C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48795083A 1983-04-25 1983-04-25

Publications (3)

Publication Number Publication Date
NO841613L NO841613L (no) 1984-10-26
NO174302B NO174302B (no) 1994-01-03
NO174302C true NO174302C (no) 1994-04-13

Family

ID=23937779

Family Applications (1)

Application Number Title Priority Date Filing Date
NO841613A NO174302C (no) 1983-04-25 1984-04-24 Fremgangsmåte for produksjon av en human-insulin-lignende vekstfaktor

Country Status (17)

Country Link
US (1) US6642029B1 (de)
EP (2) EP0561137B1 (de)
JP (2) JP2548105B2 (de)
AT (2) ATE95236T1 (de)
AU (1) AU576757B2 (de)
DE (2) DE3486491T2 (de)
DK (1) DK204584A (de)
ES (1) ES531855A0 (de)
FI (1) FI87799C (de)
HK (1) HK65594A (de)
HU (1) HU204565B (de)
IE (2) IE60228B1 (de)
IL (1) IL71634A (de)
NO (1) NO174302C (de)
NZ (1) NZ207842A (de)
PT (1) PT78484B (de)
ZA (1) ZA842982B (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198919B1 (en) 1983-04-25 2007-04-03 Genentech, Inc. Use of alpha factor sequences in yeast expression systems
NZ207926A (en) * 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US4588684A (en) * 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
WO1985000831A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
JPS60501989A (ja) * 1983-08-10 1985-11-21 アムジエン インシュリン様成長因子の微生物発現
US4758512A (en) * 1984-03-06 1988-07-19 President And Fellows Of Harvard College Hosts and methods for producing recombinant products in high yields
DK108685A (da) * 1984-03-19 1985-09-20 Fujisawa Pharmaceutical Co Vaekstfaktor i
US4738921A (en) * 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
JP2549504B2 (ja) * 1984-12-21 1996-10-30 ア−ス製薬株式会社 Dna塩基配列、ポリペプチド分泌発現ベクター及び形質転換微生物
GB8507833D0 (en) * 1985-03-26 1985-05-01 Biogen Nv Production of human somatomedin c
US5242811A (en) * 1985-03-26 1993-09-07 Biogen, Inc. Production of human somatomedin C
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
ATE63757T1 (de) * 1985-03-28 1991-06-15 Chiron Corp Expression durch verwendung von fusionsgenen fuer proteinproduktion.
US5342921A (en) * 1985-03-28 1994-08-30 Chiron Corporation Superoxide dismutase fusion polypeptides for expression of mammalian proteins
US4783524A (en) * 1985-09-17 1988-11-08 Monsanto Company Growth factors
EP0219814B1 (de) * 1985-10-21 1991-09-11 Fujisawa Pharmaceutical Co., Ltd. Verfahren zur Herstellung von insulinähnlichem Wachstumsfaktor I (IGF-I) und Plasmid zu dessen Herstellung
GB8529014D0 (en) * 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
EP0234862A3 (de) * 1986-02-28 1988-10-05 Merck & Co. Inc. Expression rekombinanter Proteine in Hefe
EP0234871A3 (de) * 1986-02-28 1988-10-12 Merck & Co. Inc. Regulierbare Expression rekombinanter Proteine in Hefe
JPH0616716B2 (ja) * 1986-10-14 1994-03-09 塩野義製薬株式会社 酵母におけるヒトpstiの製造法
DE3726655A1 (de) * 1987-08-11 1989-02-23 Hoechst Ag Verfahren zur isolierung basischer proteine aus proteingemischen, welche solche basischen proteine enthalten
GB8723660D0 (en) * 1987-10-08 1987-11-11 British Bio Technology Synthetic gene
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
EP0327503B1 (de) * 1988-02-05 1993-03-10 Ciba-Geigy Ag Verwendung von IGF I zur Herstellung eines Präparates für die Behandlung von Nierenkrankheiten
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
GB8819826D0 (en) * 1988-08-20 1988-09-21 Kabivitrum Ab Glycosylated igf-1
GB8927008D0 (en) * 1989-11-29 1990-01-17 Ciba Geigy Novel process for the production of unfused protein in e.coli
NZ236618A (en) * 1990-01-03 1997-06-24 Ciba Geigy Ag Treating and preventing osteoporosis using insulin-like growth factor i (igf i) in conjunction with a bone antiresorptive active compound
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5612198A (en) * 1990-09-04 1997-03-18 The Salk Institute Production of insulin-like growth factor-1 in methylotrophic yeast cells
WO1992004363A1 (en) * 1990-09-04 1992-03-19 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of insulin-like growth factor-1 in methylotrophic yeast cells
CA2105064A1 (en) * 1991-04-01 1992-10-02 Martin Anthony Gleeson Genes which influence pichia proteolytic activity, and uses therefor
TW267102B (de) 1992-03-13 1996-01-01 Ciba Geigy
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
US5521086A (en) * 1993-09-16 1996-05-28 Cephalon, Inc. Secretion sequence for the production of a heterologous protein in yeast
SE9402370D0 (sv) 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
EP0779927A1 (de) * 1994-09-08 1997-06-25 Chiron Corporation Methode zur gesteigerten herstellung von insulin-ähnlichem wachstumsfaktor
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
PT1486565E (pt) 1995-10-11 2008-02-28 Novartis Vaccines & Diagnostic Combinação de pdgf, kgf, igf e igfbp para cicatrização de ferimentos
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
EP1141313A2 (de) 1998-12-31 2001-10-10 Chiron Corporation Verbesserte exprimierung von hiv polypeptiden und herstellung von virusähnliche partikeln
ATE251466T1 (de) 1999-04-08 2003-10-15 Genentech Inc Zusammensetzung auf basis gegensätzlich geladener polypeptide
ES2627445T3 (es) 2002-05-01 2017-07-28 Miltenyi Biotec Technology, Inc. Partículas de vector de lentivirus resistentes a la inactivación por el complemento
EP1667521B1 (de) 2003-09-12 2011-12-07 Tercica, Inc. Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel
EP1674113A1 (de) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Konjugate von insulinähnlichem Wachstumfaktor-1 und Poly(Ethylenglykol)
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
JP4958975B2 (ja) 2006-08-31 2012-06-20 エフ.ホフマン−ラ ロシュ アーゲー インスリン様増殖因子iの製造方法
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
NZ592151A (en) 2008-12-12 2012-10-26 Boehringer Ingelheim Int Anti-igf antibodies
CN102471769A (zh) 2009-07-17 2012-05-23 亚伦·T.·塔波尔 用于具有美容功能的细胞的遗传修饰以提高美容外观的方法和组合物
US20110152188A1 (en) 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
WO2021005604A1 (en) 2019-07-11 2021-01-14 Opko Biologics Ltd. Long-acting igf-1 or igf-1 variants and methods of producing same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411994A (en) * 1978-06-08 1983-10-25 The President And Fellows Of Harvard College Protein synthesis
US4443539A (en) 1980-02-05 1984-04-17 The Upjohn Company Process for preparing bovine growth hormone
CA1200773A (en) * 1980-02-29 1986-02-18 William J. Rutter Expression linkers
AU545912B2 (en) * 1980-03-10 1985-08-08 Cetus Corporation Cloned heterologous jive products in bacillies
US4350764A (en) * 1980-03-10 1982-09-21 The Regents Of The University Of California Microbiological synthesis of beta endorphin
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4546082A (en) 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
EP0116201B1 (de) * 1983-01-12 1992-04-22 Chiron Corporation Sekretorische Expression in Eukaryoten
SE8300693L (sv) * 1983-02-09 1984-08-10 Sven Lofdahl Sett att framstella och isolera proteiner och polypeptider samt en hybridvektor for detta
GB8308483D0 (en) * 1983-03-28 1983-05-05 Health Lab Service Board Secretion of gene products
JPS60501140A (ja) * 1983-04-22 1985-07-25 アムジエン 酵母による外因性ポリペプチドの分泌
NZ207926A (en) * 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
AU2722184A (en) * 1983-04-25 1984-11-01 Genentech Inc. Use of alpha sequences in yeast expression systems
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
WO1985000831A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
US4745179A (en) * 1984-04-02 1988-05-17 Fujisawa Pharmaceutical Co., Ltd. 59 Valine insulin-like growth factor I and process for production thereof
CA1341423C (en) * 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
EP0193112A3 (de) 1985-02-22 1987-02-25 The Trustees Of Columbia University In The City Of New York Für einen insulinähnlichen Säugetier-Wachstumsfaktor II kodierende cDNS
US5084384A (en) * 1987-04-23 1992-01-28 Monsanto Company Secretion of insulin-like growth factor-I
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
GB8927008D0 (en) * 1989-11-29 1990-01-17 Ciba Geigy Novel process for the production of unfused protein in e.coli
WO1992004363A1 (en) * 1990-09-04 1992-03-19 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of insulin-like growth factor-1 in methylotrophic yeast cells
US5521086A (en) * 1993-09-16 1996-05-28 Cephalon, Inc. Secretion sequence for the production of a heterologous protein in yeast
EP0948538B1 (de) 1996-12-13 2008-06-11 Novartis Vaccines and Diagnostics, Inc. Analyse und separation von pdgf-proteinen

Also Published As

Publication number Publication date
EP0561137A1 (de) 1993-09-22
EP0561137B1 (de) 2002-07-03
DE3486216D1 (de) 1993-11-04
NO841613L (no) 1984-10-26
DK204584A (da) 1984-10-26
DE3486491T2 (de) 2003-01-16
PT78484B (fr) 1986-05-22
US6642029B1 (en) 2003-11-04
DE3486491D1 (de) 2002-08-08
HU204565B (en) 1992-01-28
EP0123228B1 (de) 1993-09-29
HUT34236A (en) 1985-02-28
JP2548105B2 (ja) 1996-10-30
FI841524A0 (fi) 1984-04-16
DE3486216T2 (de) 1994-02-17
IE940140L (en) 1984-10-25
ES8505412A1 (es) 1985-05-16
PT78484A (fr) 1984-05-01
IL71634A0 (en) 1984-07-31
AU2723384A (en) 1984-11-01
ATE220101T1 (de) 2002-07-15
EP0123228A2 (de) 1984-10-31
HK65594A (en) 1994-07-15
ATE95236T1 (de) 1993-10-15
IL71634A (en) 1992-09-06
ES531855A0 (es) 1985-05-16
FI87799C (fi) 1993-02-25
AU576757B2 (en) 1988-09-08
FI87799B (fi) 1992-11-13
FI841524A (fi) 1984-10-26
IE60228B1 (en) 1994-06-15
JPS59205997A (ja) 1984-11-21
NZ207842A (en) 1988-02-12
NO174302B (no) 1994-01-03
IE840975L (en) 1984-10-25
JP2530424B2 (ja) 1996-09-04
JPH07143886A (ja) 1995-06-06
EP0123228A3 (en) 1987-03-25
DK204584D0 (da) 1984-04-24
ZA842982B (en) 1984-11-28

Similar Documents

Publication Publication Date Title
NO174302C (no) Fremgangsmåte for produksjon av en human-insulin-lignende vekstfaktor
ATE318917T1 (de) Verfahren zur bakteriellen herstellung von heterologen polypeptiden mit disulfidbrücke
AU2443488A (en) Dna-molecules coding for fmdh control regions and structured gene for a protein having fmdh-activity and their uses
NO180381C (no) DNA-konstruksjoner inneholdende en Kluyveromyces alfa-faktor ledersekvens for utskillelse av heterologe polypeptider, ekspresjonsvektor og fremgangsmåte til fremstilling av et heterologt polypeptid i gjær
EP0494702A3 (en) Production of factor xiiia by gene technology
DE59410401D1 (de) VERFAHREN ZUR HERSTELLUNG REKOMBINANTER PilC-PROTEINE
MY103364A (en) Synthetic porcine growth hormone
EP0266057A3 (de) Eine eukaryotische sekretorische Signalsequenz enthaltendes Plasmid und Verfahren zur Sekretion der kodierten Proteine
DE3689918D1 (de) Verfahren zur Verwendung von BAR1 für die Fremdproteinsekretion.
EP0171000A3 (de) Verfahren zur Herstellung eines heterologen, reifen Proteins oder Peptids
EE03074B1 (et) Rekombinantsed eukarüootsed rakud, nende saamiseks vajalikud DNA järjestused, meetod eukarüootsete rakkude konstrueerimiseks ja sekreteeritavate valkude ning biomassi tootmismeetod
ATE91717T1 (de) Verfahren zur herstellung von proteinen in loeslicher form.
ATE122097T1 (de) Expressionsvektor und verfahren zur regulierbaren herstellung von proteinen in eukaryonten.